Renaissance Capital logo

LAVA Medtech Acquisition Priced, Nasdaq: LVACU

Blank check company targeting the medtech sector (liquidated).

Industry: SPAC

First Day Return: +1.0%

Industry: SPAC

We are a newly incorporated blank check company. Although we may pursue an acquisition in any industry or geography, we intend to capitalize on the ability of our management team to identify, acquire and operate a business that may provide opportunities for attractive risk-adjusted returns. As such, we intend to focus our investment efforts on industries that complement our management team’s background within healthcare and healthcare-related industries, primarily in the United States and Canada. Specifically, we intend to prioritize innovative, development- or early commercial-stage companies focused on clinically-impactful and high growth opportunities within medical devices, diagnostics, and digital health (comprehensively referred to as “MedTech”), which we believe are opportunity-rich, but somewhat overlooked areas relative to the strategies of most other blank check companies currently outstanding, particularly those focused on the healthcare sector. We believe our management team’s decades of relevant operational and healthcare venture investing background is substantial and can have a transformative impact on a target MedTech business.
more less
IPO Data
IPO File Date 10/01/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 10.0
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/26/2021
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $100
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Waltham, MA, United States
Founded 2021
Employees at IPO 4
Website www.lavamedtechacquisition.com

LAVA Medtech Acquisition (LVACU) Performance